Anixa Biosciences Inc 10-Q

Item 1. Financial Statements. ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (in thousands, except share and per share data) July 31, 2024 October 31, 2023 ASSETS Current assets: Cash and cash equivalents $ 1,225 $ 915 Short-term investments 19,520 22,929 Receivables 410 270 Prepaid expenses and other current assets 1,515 1,242 Total current assets 22,670 25,356 Operating lease right-of-use asset 238 166 Total assets $ 22,908 $ 25,522 LIABILITIES AND EQUITY Current liabilities: Accounts payable $ 302 $ 206 Accrued expenses 1,678 1,770 Operating lease liability 24 52 Total current liabilities 2,004 2,028 Operating lease liability, non-current 213 123 Total liabilities 2,217 2,151 Commitments and contingencies (Note 10) - - Equity: Shareholders’ equity: Preferred stock, par value $ 100 per share; 19,860 shares authorized; no shares issued or outstanding - - Series A convertible preferred stock, par value $ 100 per share; 140 shares authorized; no shares issued or outstanding - - Preferred stock, value - - Common stock, par value $ .01 per share; 100,000,000 shares authorized; 32,146,460 and 31,145,219 shares issued and outstanding as of July 31, 2024 and October 31, 2023, respectively 321 311 Additional paid-in capital 259,317 252,222 Accumulated deficit ( 237,867 ) ( 228,196 ) Total shareholders’ equity 21,771 24,337 Noncontrolling interest (Note 2) ( 1,080 ) ( 966 ) Total equity 20,691 23,371 Total liabilities and equity $ 22,908 $ 25,522 The accompanying notes are an integral part of these condensed consolidated financial statements. 1 ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (in thousands, except per share data) 2024 2023 2024 2023 For the three months ended For the nine months ended July 31, July 31, 2024 2023 2024 2023 Revenue $ - $ - $ - $ 210 Operating costs and expenses: Inventor royalties, contingent legal fees, litigation and licensing expenses - - - 161 Research and development expenses (including non-cash stock-based compensation expenses of $ 462 , $ 520 , $ 1,471 and $ 1,517 , respectively) 1,925 1,088 4,920 3,154 General and administrative expenses (including non-cash stock-based compensation expenses of $ 717 , $ 697 , $ 2,228 and $ 1,990 , respectively) 1,667 1,756 5,748 4,855 Total operating costs and expenses 3,592 2,844 10,668 8,170 Loss from operations ( 3,592 ) ( 2,844 ) ( 10,668 ) ( 7,960 ) Interest income 277 296 883 751 Net loss ( 3,315 ) ( 2,548 ) ( 9,785 ) ( 7,209 ) Less: Net loss attributable to noncontrolling interest ( 38 ) ( 37 ) ( 114 ) ( 88 ) Net loss attributable to common shareholders $ ( 3,277 ) $ ( 2,511 ) $ ( 9,671 ) $ ( 7,121 ) Net loss per common share attributable to common shareholders: Basic and diluted $ ( 0.10 ) $ ( 0.08 ) $ ( 0.30 ) $ ( 0.23 ) Weighted average common shares outstanding: Basic and diluted 32,054 30,974 31,804 30,941 The accompanying notes are an integral part of these condensed consolidated financial statements. 2 ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED ) (in thousands, except share data) FOR THE THREE MONTHS ENDED JULY 31, 2024 Shares Par Value Additional Paid-in Capital Accumulated Deficit Total Shareholders’ Equity Non- controlling Interest Total Equity Common Stock Shares Par Value Additional Paid-in Capital Accumulated Deficit Total Shareholders’ Equity Non- controlling Interest Total Equity Balance, April 30, 2024 32,006,460 $ 320 $ 257,893 $ ( 234,590 ) $ 23,623 $ ( 1,042 ) $ 22,581 Stock option compensation to employees and directors - - 1,094 - 1,094 - 1,094 Stock options issued to consultants - - 23 - 23 - 23 Offering expenses related to an at-the-market offering - - ( 45 ) - ( 45 ) - ( 45 ) Common stock issued in an at-the-market offering, net of offering expenses of $139 Common stock issued in an at-the-market offering, net of offering expenses of $139, shares Common stock issued upon exercise of stock options 80,000 1 193 - 194 - 194 Common stock issued to consultants 60,000 - 159 - 159 - 159 Common stock issued pursuant to an employee stock purchase plan Common stock issued pursuant to an employee stock purchase plan, shares Net loss - - - ( 3,277 ) ( 3,277 ) ( 38 ) ( 3,315 ) Balance, July 31, 2024 32,146,460 $ 321 $ 259,317 $ ( 237,867 ) $ 21,771 $ ( 1,080 ) $ 20,691 FOR THE THREE MONTHS ENDED JULY 31, 2023 Shares Par Value Additional Paid-in Capital Accumulated Deficit Total Shareholders’ Equity Non- controlling Interest Total Equity Common Stock Shares Par Value Additional Paid-in Capital Accumulated Deficit Total Shareholders’ Equity Non- controlling Interest Total Equity Balance, April 30, 2023 30,958,665 $ 310 $ 249,496 $ ( 222,995 ) $ 26,811 $ ( 898 ) $ 25,913 Stock option compensation to employees and directors - - 1,153 - 1,153 - 1,153 Stock options issued to consultants - - 47 - 47 - 47 Common stock issued upon exercise of stock options 55,029 - 3 - 3 - 3 Common stock issued to consultants 4,076 - 17 - 17 - 17 Net loss - - - ( 2,511 ) ( 2,511 ) ( 37 ) ( 2,548 ) Balance, July 31, 2023 31,017,770 $ 310 $ 250,716 $ ( 225,506 ) $ 25,520 $ ( 935 ) $ 24,585 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED ) (in thousands, except share data) FOR THE NINE MONTHS ENDED JULY 31, 2024 Shares Par Value Additional Paid-in Capital Accumulated Deficit Total Shareholders’ Equity Non- controlling Interest Total Equity Common Stock Shares Par Value Additional Paid-in Capital Accumulated Deficit Total Shareholders’ Equity Non- controlling Interest Total Equity Balance, October 31, 2023 31,145,219 $ 311 $ 252,222 $ ( 228,196 ) $ 24,337 $ ( 966 ) $ 23,371 Stock option compensation to employees and directors - - 3,440 - 3,440 - 3,440 Stock options issued to consultants - - 101 - 101 - 101 Common stock issued in an at-the-market offering, net of offering expenses of $ 139 785,290 8 2,976 - 2,984 - 2,984 Common stock issued upon exercise of stock options 123,999 1 317 - 318 - 318 Common stock issued to consultants 89,336 1 254 - 255 - 255 Common stock issued pursuant to an employee stock purchase plan 2,616 - 7 - 7 - 7 Net loss - - - ( 9,671 ) ( 9,671 ) ( 114 ) ( 9,785 ) Balance, July 31, 2024 32,146,460 $ 321 $ 259,317 $ ( 237,867 ) $ 21,771 $ ( 1,080 ) $ 20,691 FOR THE NINE MONTHS ENDED JULY 31, 2023 Shares Par Value Additional Paid-in Capital Accumulated Deficit Total Shareholders’ Equity Non- controlling Interest Total Equity Common Stock Shares Par Value Additional Paid-in Capital Accumulated Deficit Total Shareholders’ Equity Non- controlling Interest Total Equity Balance, October 31, 2022 30,913,902 $ 309 $ 247,123 $ ( 218,385 ) $ 29,047 $ ( 847 ) $ 28,200 Balance 30,913,902 $ 309 $ 247,123 $ ( 218,385 ) $ 29,047 $ ( 847 ) $ 28,200 Stock option compensation to employees and directors - - 3,265 - 3,265 - 3,265 Stock options issued to consultants - - 175 - 175 - 175 Common stock issued upon exercise of stock options 84,411 1 80 - 81 - 81 Common stock issued to consultants 17,554 - 67 - 67 - 67 Common stock issued pursuant to an employee stock purchase plan 1,903 - 6 - 6 - 6 Net loss - - - ( 7,121 ) ( 7,121 ) ( 88 ) ( 7,209 ) Balance, July 31, 2023 31,017,770 $ 310 $ 250,716 $ ( 225,506 ) $ 25,520 $ ( 935 ) $ 24,585 Balance 31,017,770 $ 310 $ 250,716 $ ( 225,506 ) $ 25,520 $ ( 935 ) $ 24,585 The accompanying notes are an integral part of these condensed consolidated financial statements. 4 ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (in thousands) 2024 2023 For the nine months ended July 31, 2024 2023 Cash flows from operating activities: Reconciliation of net loss to net cash used in operating activities: Net loss $ ( 9,785 ) $ ( 7,209 ) Stock option compensation to employees and directors 3,440 3,265 Stock options issued to consultants 101 175 Common stock issued to consultants 255 67 Amortization of operating lease right-of-use asset 28 34 Change in operating assets and liabilities: Receivables ( 140 ) ( 288 ) Prepaid expenses and other current assets ( 273 ) ( 65 ) Accounts payable 96 ( 171 ) Accrued expenses ( 92 ) ( 14 ) Operating lease liability ( 38 ) ( 34 ) Net cash used in operating activities ( 6,408 ) ( 4,240 ) Cash flows from investing activities: Disbursements to acquire short-term investments ( 47,307 ) ( 27,502 ) Proceeds from maturities of short-term investments 50,716 22,493 Net cash provided by (used in) investing activities 3,409 ( 5,009 ) Cash flows from financing activities: Proceeds from sale of common stock in an at-the-market offering, net of offering expenses of $ 139 2,984 - Proceeds from sale of common stock pursuant to an employee stock purchase plan 7 6 Proceeds from exercise of stock options 318 81 Net cash provided by financing activities 3,309 87 Net increase (decrease) in cash and cash equivalents 310 ( 9,162 ) Cash and cash equivalents at beginning of period 915 12,360 Cash and cash equivalents at end of period $ 1,225 $ 3,198 Supplemental disclosure of non-cash investing activity: Operating lease right-of-use asset $ ( 100 ) $ - Supplemental disclosure of non-cash financing activity: Operating lease liability $ 100 $ - The accompanying notes are an integral part of these condensed consolidated financial statements. 5 ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) 1. BUSINESS AND FUNDING Description of Business As used herein, “we,” “us,” “our,” the “Company” or “Anixa” means Anixa Biosciences, Inc. and its consolidated subsidiaries unless otherwise indicated. Anixa Biosciences, Inc. is a biotechnology company developing vaccines and therapies that are focused on critical unmet needs in oncology. Our vaccine programs include (i) the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (“TNBC”), the most lethal form of breast cancer, (ii) the development of a vaccine against ovarian cancer, and (iii) a vaccine discovery program utilizing the same mechanism as our breast and ovarian cancer vaccines, to develop additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon and prostate. Our therapeutics programs include (i) the development of a chimeric endocrine receptor T cell therapy, a novel form of chimeric antigen receptor T cell (“CAR-T”) technology, initially focused on treating ovarian cancer, which is being developed at our subsidiary, Certainty Therapeutics, Inc. (“Certainty”), and (ii) until March 2023, the development of anti-viral drug candidates for the treatment of Covid-19. We hold an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by The Cleveland Clinic Foundation (“Cleveland Clinic”) relating to certain breast cancer vaccine technology developed at Cleveland Clinic. The license agreement requires us to make certain cash payments to Cleveland Clinic upon achievement of specific development milestones. Utilizing this technology, we are working in collaboration with Cleveland Clinic to develop a method to vaccinate women against contracting breast cancer, focused initially on TNBC. The focus of this vaccine is a specific protein, α-lactalbumin, that is only expressed during lactation in a healthy woman’s mammary tissue. This protein disappears when the woman is no longer lactating, but reappears in many forms of breast cancer, especially TNBC. Studies have shown that vaccinating against this protein prevents breast cancer in mice. In October 2021, following the U.S. Food and Drug Administration’s (“FDA”) authorization to proceed, we commenced dosing patients in a Phase 1 clinical trial of our breast cancer vaccine. This study, which is being fully funded by a U.S. Department of Defense grant to Cleveland Clinic, is a multiple-ascending dose Phase 1 trial to determine the maximum tolerated dose (“MTD”) of the vaccine in patients with early-stage, triple-negative breast cancer as well as monitor immune response. The study is being conducted at Cleveland Clinic. During the course of the Phase 1 study, participants will receive three vaccinations, each two weeks apart, and will be closely monitored for side effects and immune response. The first segment of the study, Phase 1a, will consist of approximately 24 patients who have completed treatment for early-stage, triple-negative breast cancer within the past three years and are currently tumor-free but at high risk for recurrence. Studies show that 42% of TNBC patients will have a recurrence of their cancer, with most of the recurrences occurring in the first two to three years after standard of care treatment. In January 2023, the number of participants in each dose cohort was expanded, and as of August 2023, we had completed vaccinating all patients in these expanded cohorts. In December 2023, we presented the immunological data collected to date at the San Antonio Breast Cancer Symposium. The data presented show that in the vaccinated women who had been tested to date, various levels of antigen-specific T cell responses were observed at all dose levels. Subsequently, we began vaccinating participants in additional dose cohorts at varying dose levels of the different key components of the vaccine. Further, in November 2023, we commenced vaccination of participants in the second segment of the trial, Phase 1b, that includes participants who have never had cancer, but carry certain mutations in genes such as BRCA1, BRCA2 or PALB2, that indicate a greater risk of developing TNBC in the future, and have elected to have a prophylactic mastectomy. Finally, in January 2024, we commenced vaccination of participants in the third segment of the trial, Phase 1c, that includes post-operative TNBC patients that have residual disease following treatment and are currently undergoing treatment with pembrolizumab (Keytruda®). We anticipate presenting the most recent data from each of the three arms of the trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2024. 6 We hold an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by Cleveland Clinic relating to certain ovarian cancer vaccine technology. The license agreement requires us to make certain cash payments to Cleveland Clinic upon achievement of specific development milestones. This technology pertains to among other things, the use of vaccines for the treatment or prevention of ovarian cancers which express the anti-Mullerian hormone receptor 2 protein containing an extracellular domain (“AMHR2-ED”). In healthy tissue, this protein regulates growth and development of egg-containing follicles in the ovary. While expression of AMHR2-ED naturally and markedly declines during menopause, this protein is expressed at high levels in the ovaries of postmenopausal women with ovarian cancer. Researchers at Cleveland Clinic believe that a vaccine targeting AMHR2-ED could prevent the occurrence of ovarian cancer. In May 2021, Cleveland Clinic was granted acceptance for our ovarian cancer vaccine technology into the National Cancer Institute’s (“NCI”) PREVENT program. The NCI is a part of the National Institutes of Health (“NIH”). The PREVENT program is a peer-reviewed agent development program designed to support pre-clinical development of innovative interventions and biomarkers for cancer prevention and interception towards clinical trials. The scientific and financial resources of the PREVENT program are being used for our ovarian cancer vaccine technology to perform virtually all pre-clinical research and development, manufacturing and Investigational New Drug (“IND”) application enabling studies. This work is being performed at NCI facilities, by NCI scientific staff and with NCI financial resources and will require no material financial expenditures by the Company, nor the payment of any future consideration by the Company to NCI. In May 2024, based on the positive clinical results to date in the development of our breast cancer vaccine, we entered into a Joint Development and Option Agreement with Cleveland Clinic to collaborate in efforts to develop additional vaccines for the prevention or treatment of cancers. Working with Cleveland Clinic researchers, we will focus on the same novel scientific mechanism as in our breast and ovarian cancer vaccines, and work to discover additional retired proteins that may be associated with other forms of cancer, specifically high incidence malignancies in the lung, colon and prostate. Our subsidiary, Certainty, is developing immuno-therapy drugs against cancer. Certainty holds an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by The Wistar Institute (“Wistar”), the nation’s first independent biomedical research institute and a leading NCI designated cancer research center, relating to Wistar’s chimeric endocrine receptor targeted therapy technology. We have initially focused on the development of a treatment for ovarian cancer, but we also may pursue applications of the technology for the development of treatments for additional solid tumors. The license agreement requires Certainty to make certain cash and equity payments to Wistar upon achievement of specific development milestones. With respect to Certainty’s equity obligations to Wistar, Certainty issued to Wistar shares of its common stock equal to five percent ( 5 %) of the common stock of Certainty, such equity stake subject to dilution by further funding of Certainty’s activities by the Company. Due to such Company funding, Wistar’s equity stake in Certainty was 4.4 % as of July 31, 2024. Certainty, in collaboration with the H. Lee Moffitt Cancer Center and Research Institute, Inc. (“Moffitt”), has begun human clinical testing of the CAR-T technology licensed by Certainty from Wistar aimed initially at treating ovarian cancer. After receiving authorization from the FDA, we commenced enrollment of patients in a Phase 1 clinical trial and treated the first patient in August 2022. Further, in May 2023 and August 2023, we treated the second and third patients in the trial, respectively, at the same dose level as the first patient, and the treatment was well-tolerated by the patients. In February 2024, May 2024 and June 2024, we treated the three patients, respectively, of the second dose cohort, where the patients were administered a three-times higher dose of cells than the patients in the first cohort. The treatment appears to have been well-tolerated by the patients. While the dose levels in the first two cohorts were expected to be sub-therapeutic, two of the six patients treated to date are exhibiting some anecdotal signs of efficacy. Both have shown signs of tumor necrosis, and one is more than 16 months past initial treatment. In the case of this patient, due to the encouraging results with her initial treatment, we sought single patient IND permission from the FDA to re-dose her. This re-dosing has been approved by the FDA, and we anticipate administering her second treatment in the coming weeks. This study is a dose-escalation trial with two arms based on route of delivery—intraperitoneal or intravenous—to determine the maximum tolerated dose in patients with recurrent epithelial ovarian cancer and to assess persistence, expansion and efficacy of the modified T cells. The study is being conducted at Moffitt and will consist of up to 24 to 48 patients who have received at least two prior lines of chemotherapy. The study is estimated to be completed in two to four years depending on multiple factors including when the maximum tolerated dose is reached, the rate of patient enrollment, the significance of efficacy data and how long we maintain the two different delivery methods. 7 Over the next several quarters, we expect the development of our vaccines and therapeutics to be the primary focus of the Company. As part of our legacy operations, the Company remains engaged in limited patent licensing activities of its various patent portfolios. We do not expect these activities to be a significant part of the Company’s ongoing operations nor do we expect these activities to require material financial resources or attention of senior management. Over the past several years, our revenue was derived from technology licensing and the sale of patented technologies, including revenue from the settlement of litigation. We have not generated any revenue to date from our vaccine or therapeutics programs. In addition, while we pursue our vaccine and therapeutics programs, we may also make investments in and form new companies to develop additional emerging technologies. We do not expect to begin generating revenue with respect to any of our current vaccine or therapy programs in the near term. We hope to achieve a profitable outcome by eventually licensing our technologies to large pharmaceutical companies that have the resources and infrastructure in place to manufacture, market and sell our technologies as vaccines or therapeutics. The eventual licensing of any of our technologies may take several years, if it is to occur at all, and may depend on positive results from human clinical trials. Funding and Management’s Plans Based on currently available information as of September 6, 2024, we believe that our existing cash, cash equivalents, short-term investments and expected cash flows will be sufficient to fund our activities for at least the next twelve months. The Company has approximately $ 20,745,000 of cash, cash equivalents, and short-term investments at July 31, 2024 compared to approximately $ 23,844,000 at October 31, 2023 which is a reduction of approximately $ 3,099,000 during the nine months ended July 31, 2024. Therefore, the Company believes that it has sufficient cash, cash equivalents, and short-term investments to operate its business, as currently contemplated, for significantly longer than 12 months from the date of this Report. We have implemented a business model that conserves funds by collaborating with third parties to develop our technologies. During the nine months ended July 31, 2024, we raised approximately $ 2,984,000 , net of expenses, through an at-the-market equity offering of 785,290 shares of common stock, under which offering we may issue up to $ 100 million of common stock. Under our at-the-market equity program, which is currently effective and may remain available for us to use in the future, as of July 31, 2024, we may sell an additional approximately $ 97 million of common stock. 2. SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, certain information and disclosures required by generally accepted accounting principles in annual financial statements have been omitted or condensed. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures included in our Annual Report on Form 10-K for the fiscal year ended October 31, 2023. The accompanying October 31, 2023 condensed consolidated balance sheet data was derived from the audited financial statements but does not include all disclosures required by US GAAP. The condensed consolidated financial statements include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of our financial position as of July 31, 2024, and results of operations and cash flows for the interim periods represented. The results of operations for the three and nine months ended July 31, 2024 are not necessarily indicative of the results to be expected for the year. 8 Noncontrolling Interest Noncontrolling interest represents Wistar’s equity ownership in Certainty and is presented as a component of equity. The following table sets forth the changes in noncontrolling interest for the nine months ended July 31, 2024 (in thousands): SCHEDULE OF CHANGES IN NONCONTROLLING INTEREST Balance, October 31, 2023 $ ( 966 ) Net loss attributable to noncontrolling interest ( 114 ) Balance, July 31, 2024 $ ( 1,080 ) Revenue Recognition Our revenue has been derived solely from technology licensing and the sale of patented technologies. Revenue is recognized upon transfer of control of intellectual property rights and satisfaction of other contractual performance obligations to licensees in an amount that reflects the consideration we expect to receive. Our revenue recognition policy requires us to make certain judgments and estimates in connection with the accounting for revenue. Such areas may include determining the existence of a contract and identifying each party’s rights and obligations to transfer goods and services, identifying the performance obligations in the contract, determining the transaction price and allocating the transaction price to separate performance obligations, estimating the timing of satisfaction of performance obligations, determining whether a promise to grant a license is distinct from other promised goods or services and evaluating whether a license transfers to a customer at a point in time or over time. Our revenue arrangements provide for the payment, within 30 days of execution of the agreement, of contractually determined, one-time, paid-up license fees in settlement of litigation and in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. These arrangements typically include some combination of the following: (i) the grant of a non-exclusive, retroactive and future license to manufacture and/or sell products covered by patented technologies owned or controlled by the Company, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and (iv) the dismissal of any pending litigation. In such instances, the intellectual property rights granted have been perpetual in nature, extending until the expiration of the related patents. Pursuant to the terms of these agreements, we have no further obligations with respect to the granted intellectual property rights, including no obligation to maintain or upgrade the technology, or provide future support or services. Licensees obtained control of the intellectual property rights they have acquired upon execution of the agreement. Accordingly, the performance obligations from these agreements were satisfied and 100 % of the revenue was recognized upon the execution of the agreements. Cost of Revenues Cost of revenues include the costs and expenses incurred in connection with our patent licensing and enforcement activities, including inventor royalties paid to original patent owners, contingent legal fees paid to external counsel, other patent-related legal expenses paid to external counsel and licensing and enforcement related research, consulting and other expenses paid to third-parties. These costs are included under the caption “Operating costs and expenses” in the accompanying condensed consolidated statements of operations. 9 Research and Development Expenses Research and development expenses consist primarily of employee compensation, payments to third parties for research and development activities and other direct costs associated with developing our therapeutics and vaccines. We recognize research and development expenses as incurred. Advance payments for future research and development activities are deferred and expensed as the services are performed. We recognize our preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions, clinical research organizations (“CROs”), clinical manufacturing organizations (“CMOs”), and other parties that conduct and manage various stages of research and development activities on our behalf. Fees for such services are recognized based on management’s estimates after considering the activities and tasks completed by each service provider in a given period, the time period over which services are expected to be performed, and the level of effort expended in each reporting period. Investment Policy The Company’s investment policy is to acquire U.S. government debt securities with fixed maturities and contractual cash flows that the Company has the positive intent and ability to hold to maturity. These securities are recorded at amortized cost, net of any applicable discount which is amortized to interest income, and are accounted for as held-to-maturity securities. 3. STOCK-BASED COMPENSATION The Company maintains stock equity incentive plans under which the Company grants incentive stock options, non-qualified stock options, stock appreciation rights, stock awards, performance awards, or stock units to employees, directors and consultants. Stock Option Compensation Expense We account for stock options granted to employees, directors and others using the accounting guidance in ASC 718, Stock Compensation (“ASC 718”). We estimate the fair value of service-based stock options on the date of grant, using the Black-Scholes pricing model, and recognize compensation expense over the requisite service period of the grant. We recorded stock-based compensation expense related to service-based stock options granted to employees and directors of approximately $ 1,094,000 and $ 1,153,000 during the three months ended July 31, 2024 and 2023, respectively, and approximately $ 3,440,000 and $ 3,265,000 during the nine months ended July 31, 2024 and 2023, respectively. The compensation cost for service-based stock options granted to consultants is measured at the grant date, based on the fair value of the award using the Black-Scholes pricing model, and is expensed on a straight-line basis over the requisite service period (the vesting period of the stock option) which is one to three years. We recorded stock-based consulting expense related to stock options granted to consultants of approximately $ 23,000 and $ 47,000 during the three months ended July 31, 2024 and 2023, respectively, and approximately $ 101,000 and $ 175,000 during the nine months ended July 31, 2024 and 2023, respectively. Stock Option Plans During the three and nine months ended July 31, 2024, we had two stock option plans: the Anixa Biosciences, Inc. 2010 Share Incentive Plan (the “2010 Share Plan”) and the Anixa Biosciences, Inc. 2018 Share Incentive Plan (the “2018 Share Plan”), which were adopted by our Board of Directors on July 14, 2010 and January 25, 2018, respectively. The 2018 Share Plan was approved by our shareholders on March 29, 2018. Stock Option Activity During the three months ended July 31, 2024 and 2023, we did not grant any options to purchase shares of common stock, and during the nine months ended July 31, 2024 and 2023, we granted options to purchase 1,350,000 shares and 1,505,000 shares of common stock, respectively, to employees, directors and consultants, with exercise prices ranging from $ 3.17 to $ 4.39 per share, pursuant to the 2018 Share Plan. During the three months ended July 31, 2024, stock options to purchase 80,000 shares of common stock were exercised on a cash basis, with aggregate proceeds of approximately $ 194,000 . During the three months ended July 31, 2023, stock options to purchase 160,000 shares of common stock, of which 115,417 shares were withheld, were exercised on a cashless basis and stock options to purchase 10,446 shares of common stock were exercised on a cash basis, with aggregate proceeds of approximately $ 3,000 . During the nine months ended July 31, 2024, stock options to purchase 123,999 shares of common stock were exercised on a cash basis, with aggregate proceeds of approximately $ 318,000 . During the nine months ended July 31, 2023, stock options to purchase 161,111 shares of common stock, of which 116,225 shares were withheld, were exercised on a cashless basis and stock options to purchase 39,525 shares of common stock were exercised on a cash basis, with aggregate proceeds of approximately $ 81,000 . 10 2010 Share Plan The 2010 Share Plan provided for the grant of nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. In accordance with the provisions of the 2010 Share Plan, the plan terminated with respect to the ability to grant future awards on July 14, 2020. Information regarding the 2010 Share Plan for the nine months ended Jul 31, 2024 is as follows: SCHEDULE OF OPTION ACTIVITY Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value (in thousands) Options outstanding at October 31, 2023 1,189,000 $ 2.94 Granted 1,350,000 $ 4.38 Exercised ( 63,000 ) $ 2.40 Expirations ( 313,907 ) $ 4.21 Options outstanding and exercisable at July 31, 2024 1,126,000 $ 2.97 $ 822 The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of July 31, 2024: SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE Range of Exercise Prices Number Outstanding and Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 0.67 - $ 2.27 316,000 3.0 $ 1.11 $ 2.58 - $ 3.13 301,000 1.5 $ 2.91 $ 3.46 - $ 5.30 509,000 3.1 $ 4.17 2018 Share Plan The 2018 Share Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. As of July 31, 2024, the 2018 Share Plan had 938,907 shares available for future grants. Information regarding the 2018 Share Plan for the nine months ended July 31, 2024 is as follows: SCHEDULE OF OPTION ACTIVITY Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value (in thousands) Options outstanding at October 31, 2023 10,241,000 $ 3.67 Granted 1,350,000 $ 4.38 Exercised ( 60,999 ) $ 2.73 Expirations ( 313,907 ) $ 4.21 Options outstanding at July 31, 2024 11,216,094 $ 3.74 $ 1,513 Options exercisable at July 31, 2024 7,695,385 $ 3.55 $ 1,381 11 The following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of July 31, 2024: SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 2.09 - $ 3.87 5,353,879 5.7 $ 3.24 5,028,261 5.5 $ 3.26 $ 3.96 - $ 5.30 5,862,215 7.7 $ 4.20 2,667,124 7.1 $ 4.09 Employee Stock Purchase Plan The Company maintains the Anixa Biosciences, Inc. Employee Stock Purchase Plan (the “ESPP”) which permits eligible employees to purchase shares at not less than 85 % of the market value of the Company’s common stock on the offering date or the purchase date of the applicable offering period, whichever is lower. The ESPP was adopted by our Board of Directors on August 13, 2018 and approved by our shareholders on September 27, 2018. During the three and nine months ended July 31, 2024 and 2023, employees purchased 2,616 and 1,903 shares, respectively, with aggregate proceeds of approximately $ 7,000 and $ 6,000 , respectively. Warrants As of July 31, 2024, we had warrants outstanding to purchase 300,000 shares of common stock at $ 6.56 per share, issued during fiscal year 2021 and expiring on March 22, 2026. Information regarding the Company’s warrants for the nine months ended July 31, 2024 is as follows: SCHEDULE OF WARRANTS ACTIVITY Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Warrants outstanding at October 31, 2023 300,000 $ 6.56 Warrants outstanding and exercisable at July 31, 2024 300,000 $ 6.56 $ 0 The following table summarizes information about the Company’s outstanding and exercisable warrants as of July 31, 2024: SCHEDULE OF OUTSTANDING AND EXERCISABLE Range of Exercise Prices Number Outstanding and Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 6.56 300,000 1.6 $ 6.56 Stock Awards During the three months ended July 31, 2024 and 2023, we issued 60,000 shares and 4,076 shares of common stock, respectively, to consultants providing investor relations services and recorded expense of approximately $ 62,000 and $ 17,000 , respectively. During the nine months ended July 31, 2024 and 2023, we issued 89,336 shares and 17,554 shares of common stock, respectively, to consultants providing investor relations services and recorded expense of approximately $ 158,000 and $ 67,000 , respectively. As of July 31, 2024 and 2023, approximately $ 97,000 and $ 0 , respectively, was recorded as a prepaid expense. 4. FAIR VALUE MEASUREMENTS US GAAP defines fair value and establishes a framework for measuring fair value. We have categorized our financial assets and liabilities, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy as set forth below. If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. 12 Financial assets and liabilities recorded in the accompanying condensed consolidated balance sheets are categorized based on the inputs to the valuation techniques as follows: Level 1 – Financial instruments whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which we have the ability to access at the measurement date. Level 2 – Financial instruments whose values are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets. Level 3 – Financial instruments whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the instrument. The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of July 31, 2024 (in thousands): SCHEDULE OF FINANCIAL ASSETS MEASURED AT FAIR VALUE ON A RECURRING BASIS Level 1 Level 2 Level 3 Total Money market funds: Cash equivalents $ 1,090 $ - $ - $ 1,090 U.S. treasury bills Short-term investments - 19,520 - 19,520 Total financial assets $ 1,090 $ 19,520 $ - $ 20,610 The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of October 31, 2023 (in thousands): Level 1 Level 2 Level 3 Total Money market funds: Cash equivalents $ 778 $ - $ - $ 778 Certificates of deposit: Short term investments - 720 - 720 U.S. treasury bills: Short-term investments - 22,209 - 22,209 Total financial assets $ 778 $ 22,929 $ - $ 23,707 Our non-financial assets that are measured on a non-recurring basis are property and equipment and other assets which are measured using fair value techniques whenever events or changes in circumstances indicate a condition of impairment exists. The estimated fair value of prepaid expenses and other current assets, accounts payable and accrued expenses approximates their individual carrying amounts due to the short-term nature of these measurements. Cash equivalents are stated at carrying value which approximates fair value. 5. ACCRUED EXPENSES Accrued expenses consist of the following as of: SCHEDULE OF ACCRUED EXPENSES July 31, October 31, 2024 2023 (in thousands) Payroll and related expenses $ 900 $ 1,114 Accrued royalty and contingent legal fees 626 626 Accrued other 152 30 Accrued expenses $ 1,678 $ 1,770 13 6. NET LOSS PER SHARE OF COMMON STOCK Basic net loss per common share (“Basic EPS”) is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss per common share (“Diluted EPS”) is computed by dividing net loss by the weighted average number of common shares and dilutive common share equivalents and convertible securities then outstanding. Diluted EPS for all periods presented is the same as Basic EPS, as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive. For this reason, excluded from the calculation of Diluted EPS for the nine months ended July 31, 2024 and 2023, were stock options to purchase 12,342,094 and 11,473,236 shares, respectively, and warrants to purchase 300,000 and 300,000 shares, respectively. 7. EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS In October 2021, the FASB issued Accounting Standards Update 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, to require that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. The amendments in this update should be applied prospectively and are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures. In November 2023, the FASB issued Accounting Standards Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, to provide more disaggregated expense information about a public entity’s reportable segments. The amendments in this update should be applied retrospectively and are effective for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. We began a detailed assessment of the impact that this guidance will have on our consolidated financial statements and related disclosures, and our analysis is currently ongoing. In December 2023, the FASB issued Accounting Standards Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, to require disaggregated information about a reporting entity’s effect tax rate reconciliation as well as information on income taxes paid. The amendments in this update should be applied prospectively, with an option to apply them retrospectively, and are effective for fiscal years beginning after December 15, 2024 for public entities. We began a detailed assessment of the impact that this guidance will have on our consolidated financial statements and related disclosures, and our analysis is currently ongoing. 8. INCOME TAXES We recognize deferred tax assets and liabilities for the estimated future tax effects of events that have been recognized in our financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount expected to be realized. We have provided a full valuation allowance against our deferred tax asset due to our historical pre-tax losses and the uncertainty regarding the realizability of these deferred tax assets. We have substantial net operating loss carryforwards for Federal and California income tax returns. These net operating loss carryforwards could be subject to limitations under Internal Revenue Code section 382, the effects of which have not been determined by the Company. We have no unrecognized income tax benefits as of July 31, 2024 and October 31, 2023 and we account for interest and penalties related to income tax matters, if any, in general and administrative expenses. 9. LEASES We lease approximately 2,000 square feet of office space at 3150 Almaden Expressway, San Jose, California (our principal executive offices) from an unrelated party pursuant to an operating lease that, as amended, will expire on September 30, 2027 , with an option to extend the lease an additional two years . Our base rent is approximately $ 5,000 per month and the lease provides for annual increases of approximately 3 % and an escalation clause for increases in certain operating costs. The lease, as amended, resulted in a right-of-use asset and lease liability of approximately $ 250,000 with a discount rate of 12 %. Rent expense was approximately $ 16,000 and $ 17,000 , respectively, for the three months ended July 31, 2024 and 2023, and approximately $ 49,000 and $ 50,000 , respectively, for the nine months ended July 31, 2024 and 2023. 14 For operating leases, the lease liability is initially and subsequently measured at the present value of the unpaid lease payments. The remaining 62 -month lease term as of July 31, 2024 for the Company’s lease includes the noncancelable period of the lease and the additional two-year option period that the Company is reasonably certain to exercise. All right-of-use assets are reviewed for impairment when indications of impairment are present. As of July 31, 2024, the annual minimum future lease payments of our operating lease liabilities were as follows (in thousands): SCHEDULE OF MINIMUM LEASE PAYMENTS For Years Ended October 31, Operating Leases 2024 (remaining) $ 11 2025 56 2026 63 2027 65 2028 66 2029 63 Total future minimum lease payments, undiscounted 324 Less: Imputed interest ( 87 ) Present value of future minimum lease payments $ 237 10. COMMITMENTS AND CONTINGENCES Litigation Matters Other than lawsuits related to the enforcement of our patent rights, we are not a party to any material pending legal proceedings, nor are we aware of any pending litigation or legal proceeding against us that would have a material adverse effect upon our results of operations or financial condition. License Commitments As of July 31, 2024, our commitments under certain technology license agreements related to our therapeutic and vaccine development programs for the next twelve months, were approximately $ 150,000 . Research & Development Agreements We have entered into certain research and development agreements with various third-party vendors related to the manufacturing and stability testing of the materials necessary for the development of our breast cancer vaccine and our CAR-T therapeutic, as well as basic research related to our new cancer vaccine discovery program. As of July 31, 2024, future payments the Company may make under these agreements, dependent upon, among other things, development of analytical methods, formulation feasibility studies, stability testing, and results of manufacturing processes, may be approximately $ 4.3 million and such payments may be made over up to a five -year period. 15 11. SEGMENT INFORMATION We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in three reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines and (iii) Other. The following represents selected financial information for our segments for the three and nine months ended July 31, 2024 and 2023 and as of July 31, 2024 and October 31, 2023, in thousands: SCHEDULE OF SEGMENT INFORMATION For the Three Months Ended July 31, For the Nine Months Ended July 31, 2024 2023 2024 2023 Net loss: CAR-T Therapeutics $ ( 1,145 ) $ ( 1,091 ) $ ( 4,115 ) $ ( 2,999 ) Cancer Vaccines ( 2,160 ) ( 1,390 ) ( 5,628 ) ( 3,261 ) Other ( 10 ) ( 67 ) ( 42 ) ( 949 ) Total $ ( 3,315 ) $ ( 2,548 ) $ ( 9,785 ) $ ( 7,209 ) Net income/(loss) $ ( 3,315 ) $ ( 2,548 ) $ ( 9,785 ) $ ( 7,209 ) Total operating costs and expenses $ 3,592 $ 2,844 $ 10,668 $ 8,170 Less non-cash stock-based compensation ( 1,179 ) ( 1,217 ) ( 3,699 ) ( 3,507 ) Operating costs and expenses excluding non-cash stock-based compensation $ 2,413 $ 1,627 $ 6,969 $ 4,663 Operating costs and expenses excluding non-cash stock-based compensation: CAR-T Therapeutics $ 789 $ 713 $ 2,943 $ 1,930 Cancer Vaccines 1,614 855 3,988 1,966 Other 10 59 38 767 Total $ 2,413 $ 1,627 $ 6,969 $ 4,663 Operating costs and expenses excluding non-cash stock-based compensation $ 2,413 $ 1,627 $ 6,969 $ 4,663 July 31, 2024 October 31, 2023 Total assets: CAR-T Therapeutics $ 7,493 $ 7,523 Cancer Vaccines 15,290 17,215 Other 125 784 Total $ 22,908 $ 25,522 Total assets $ 22,908 $ 25,522 Operating costs and expenses excluding non-cash stock-based compensation is the measurement the chief operating decision-maker uses in managing the enterprise. The Company’s consolidated revenue of $ 210,000 and inventor royalties, contingent legal fees, litigation and licensing expense of $ 161,000 for the nine months ended July 31, 2023 were solely related to our encrypted audio/video conference calling technology, which is included in our Other segment. All our revenue is generated domestically (United States) based on the country in which the licensee is located. 16